Latest Medical Technology News

Page 1 of 15
Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.
Logan Eniac
Logan Eniac
14 Feb 2026
Cyclopharm Limited has completed the initial phase of a $14 million share placement, issuing nearly 9.5 million shares at 95 cents each, with the remaining shares set for issuance later this month.
Ada Torres
Ada Torres
11 Feb 2026
A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.
Logan Eniac
Logan Eniac
7 Feb 2026
A volatile week for ASX tech saw a steep sell-off in freight software, while defence AI and RegTech contract wins pulled buyers back into smaller names. Big corporate actions kept attention on what’s real: signed deals, cash timelines, and who pays whom, and when.
Logan Eniac
Logan Eniac
7 Feb 2026
Hydrix Limited has amended its quarterly cash flow report, revealing stronger customer receipts and a stable cash position supported by robust financing facilities.
Sophie Babbage
Sophie Babbage
2 Feb 2026
Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.
Ada Torres
Ada Torres
2 Feb 2026
A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.
Logan Eniac
Logan Eniac
31 Jan 2026
Next Science Limited has updated the payment date for its cash return of capital to 10 February 2026, following its recent asset sale and pending ASX delisting.
Ada Torres
Ada Torres
30 Jan 2026
4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.
Ada Torres
Ada Torres
30 Jan 2026
4DMedical has secured a commercial contract with University of Chicago Medicine to deploy its CT, VQ™ lung imaging technology, marking the fifth major US academic medical centre to adopt the platform since FDA clearance.
Ada Torres
Ada Torres
30 Jan 2026
Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.
Ada Torres
Ada Torres
30 Jan 2026
Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.
Ada Torres
Ada Torres
30 Jan 2026